Robert Bradway has been with Amgen since 2006, working in senior finance and operations strategy. Contributed photo
Robert Bradway, the CEO and chairman of global biotechnology company Amgen, has been named Boeing’s new director and elected to a board position.
Bradway has been with Amgen since 2006, working in senior finance and operations strategy as chief financial officer and chief operating officer. He was elected CEO in 2012 and chairman in 2013. He will serve on the Boeing board’s Audit and Finance committees.
"Bob brings to the Boeing board a global perspective from a company making long-term investments in an advanced high-technology and innovation-focused industry," Boeing Chairman, President and CEO Dennis Muilenburg said. "His accomplishments in business, operations and finance will serve Boeing well as he applies his broad-based experience to aerospace."
Bradway earned his undergraduate degree from Amherst College and his master’s in business administration from Harvard. He is a member of Norfolk Southern Corp.’s board of directors and on the board of trustees of the University of South California.
His volunteer work includes chairing the CEO Roundtable on Cancer, a nonprofit dedicated to cancer treatments and prevention.